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Abstract
Background: The ability to respond to changes in the extra-intracellular environment is prerequisite for cell
survival. Cellular responses to the environment include elevating defense systems, such as the antioxidant defense
system. Hypoxia-evoked reactive oxygen species (ROS)-driven oxidative stress is an underlying mechanism of retinal
ganglion cell (RGC) death that leads to blinding disorders. The protein peroxiredoxin 6 (PRDX6) plays a pleiotropic
role in negatively regulating death signaling in response to stressors, and thereby stabilizes cellular homeostasis.
Results: We have shown that RGCs exposed to hypoxia (1%) or hypoxia mimetic cobalt chloride display reduced
expression of PRDX6 with higher ROS expression and activation of NF-B. These cells undergo apoptosis, while
cells with over-expression of PRDX6 demonstrate resistance against hypoxia-driven RGC death. The RGCs exposed
to hypoxia either with 1% oxygen or cobalt chloride (0-400 μM), revealed ~30%-70% apoptotic cell death after 48
and 72 h of exposure. Western analysis and real-time PCR showed elevated expression of PRDX6 during hypoxia at
24 h, while PRDX6 protein and mRNA expression declined from 48 h onwards following hypoxia exposure.
Concomitant with this, RGCs showed increased ROS expression and activation of NF-B with IkB phosphorylation/
degradation, as examined with H2DCF-DA and transactivation assays. These hypoxia-induced adverse reactions
could be reversed by over-expression of PRDX6.
Conclusion: Because an abundance of PRDX6 in cells was able to attenuate hypoxia-induced RGC death, the
protein could possibly be developed as a novel therapeutic agent acting to postpone RGC injury and delay the
progression of glaucoma and other disorders caused by the increased-ROS-generated death signaling related to
hypoxia.
Background
Uncontrolled rises in intracellular reactive oxygen species
(ROS) are triggered by downregulation of expression and
activity of protective molecules in response to changes in
the extracellular environment. Such changes often
include hypoxia, the scarcity of oxygen can lead to cell
injury and death by apoptosis. Recent evidence has
shown an increase of intracellular ROS expression in
cells during hypoxia, with the source of the increase
being the mitochondria [1,2]. Mammalian cells respond
to fluctuations in their micro environmental oxygen by
regulating defense genes such as stress response genes,
heat shock factor, NF-B, and HIFa-1. These factors play
a decisive role in the fate of cells by activating protective
molecules such as PRDX6. However, a scarcity of oxygen
to cells also results in functional or adaptive responses
[3-6]. Conversely, prolonged hypoxia can induce genes
involved in cell death [7,8]. The increased levels of ROS
during hypoxia and ROS-driven-oxidative stress induce
deleterious effects by activating/deactivating genes and
deregulating normal survival signaling [9,10]. This pro-
cess results in pathophysiology of cells and tissues, such
as stroke, cardiovascular disease, tumorigenesis, and
development of various blinding eye conditions [11,12].
The death of retinal ganglion cells (RGCs) is a major
blinding event, and RGC death has been reported to
occur during retinal hypoxia/ischemia [13,14]. Retinal
cells that are highly active require a regular supply of
oxygen [11,15]. Any interruption in oxygen supply due to
an abnormality in circulation such as retinal artery
* Correspondence: dpsingh@unmc.edu
1Department of Ophthalmology and Visual Sciences, University of Nebraska
Medical Center, Omaha, NE, 68 198, USA
Full list of author information is available at the end of the article
Tulsawani et al. BMC Neuroscience 2010, 11:125
http://www.biomedcentral.com/1471-2202/11/125
© 2010 Tulsawani et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.occlusion or retinal vein thrombosis or atherosclerosis
results in retinal hypoxia/ischemia. An extended period
of hypoxia leads to the development of complications
such as glaucoma, optic neuropathies, diabetic retinopa-
thies, and retinal vein occlusions [16-19]. It has been
found that the inner retina is more susceptible to
hypoxia, in contrast to outer one [20]. To cope with
oxidation-induced adverse effect one natural protective
characteristic of eye is that intra-ocular O2 tensions are
low however, many other cellular defense systems are
evolved such as glycolysis, angiogenesis, vasodilation, and
erythropoiesis in response to hypoxia [21], but these pro-
tective phenomenon are momentary [22], following
which cell death and tissue damage occur [11]. Hypoxia-
induced generation of ROS results in imbalance of the
cellular oxidant-antioxidant status that leads to failure of
cellular homeostasis. ROS-driven oxidative stress is a
known cause of lipid peroxidation, protein oxidation, and
DNA oxidation, which contribute to neurodegeneration
[21,23,24]. Oxidative stress also has been reported to be
cytotoxic to RGCs [10,25], causing necrotic or apoptotic
death [10,22,26,27]. In addition, the generation of ROS is
associated with activation or deactivation of several survi-
val factors [28]. NF-B is a transcription factor which is
activated by various stimuli including oxidative stress.
NF-B plays multiple roles in cell survival, proliferation,
and differentiation and also in cell death as a pro- or
anti-apoptotic transcription factor, depending on cell
type or the nature of injury [29,30]. A wealth of informa-
tion documents that RelA containing NF-Bc o m p l e x
has an antiapoptotic effect [31]. In glaucoma, NF-Bi s
highly activated in RGCs and has been suggested to be
proapoptotic and implicated in retinal neuronal cell
death [32,33]. Initiation of apoptotic response to a variety
of stress signals via NF-B requires its translocation into
nucleus from the cytoplasm. Under normal circum-
stances, in cell cytoplasm an association between IkB, an
inhibitor protein, and NF-B dimers renders NF-B inac-
tive. IkB is a member of a family of regulator proteins,
viz. IkB-a,I k B - b,a n dB c l 3 .H o w e v e r ,i nr e s p o n s et o
stress signals, IkB undergoes phosphorylation, which
releases its inhibition of NF-B. NF-Bt r a n s l o c a t e st o
the nucleus and binds to DNA [10,34].
Moreover, the over-expression of intracellular ROS
caused by extracellular stressors is controlled by antioxi-
dant defenses such as catalase, SOD, glutathione peroxi-
dase, and, most importantly, the newly discovered
peroxiredoxins [35-39]. The peroxiredoxin (Prdx) family
includes six known members (Prdx 1-6). Of particular
interest is PRDX6 cloned by our group from human
lens epithelial cells cDNA library [40]. This agent has
GSH peroxidase as well as acidic Ca
2+-independent
phospholipase A2 activities [37,39-44]. Recently, our
group has shown that PRDX6 has protective potential in
saving RGCs against glutamate and TNF-a induced
cytotoxicity. It acts by limiting ROS and maintaining
calcium homeostasis [10,37,42,43,45-48]. The unique
ability to regulate signaling and to maintain phospholi-
pid turnover distinguishes PRDX6 from the other five
peroxiredoxins (Prdx1 to 5). This molecule is widely
expressed, occurring in high levels in the liver, lung, eye
lens, and keratinocytes [37,40,48-50] including RGCs
[9], and its reduced expression can lead to cell death
and tissue degeneration [47,48,51]. Recently, PRDX6 has
been implicated in maintaining blood vessel integrity in
wounded skin [52,53] and in development and progres-
sion of several diseases, including oxidative-induced cat-
aractogenesis [43,54], psoriasis [55,56], atherosclerosis
[51], and parkinsonian dementia [57]. Thus, accumulat-
ing evidence indicates that underexpression of PRDX6
contributes to pathophysiology of cells and tissues, and
this involves an increase in ROS levels. The increase
leads to declines in a number of physiological functions
because of overmodulation of ROS-mediated gene
expression and activation of factors, including NF-B.
Stimulation of such factors in RGC has been implicated
as a cause of the initiation of death signaling [58,59].
However, given the role of PRDX6 in maintaining cellu-
lar homeostasis by blocking death signaling and thereby
regulating ROS expression [9,10,37], we think that a
supply of PRDX6 will attenuate the hypoxia-evoked
ROS-induced deleterious signaling in RGCs. In the
study described here, we used RGCs exposed to 1% O2
and/or CoCl2, a hypoxia mimetic, as a model system to
explore the underlying event(s) of hypoxia-induced RGC
death. We have shown that RGCs facing hypoxia for
longer periods display elevated expression of ROS and
reduced levels of PRDX6, and that RGCs over-expressing
PRDX6 gain resistance against hypoxia-evoked genera-
tion of ROS and ROS-induced cellular insults, by nega-
tively regulating death signaling.
In this study, we investigated whether chronic hypoxia
evoked the production of ROS in RGCs, and whether over-
expression of ROS initiated NF-B-mediated death signal-
ing by phosphorylation/degradation of IkB, resulting in
RGC death. In addition, by using transfection and transac-
tivation assays, we showed that ROS-mediated suppression
of Prdx6 mRNA and protein expression in RGCs bearing
higher levels of ROS could be attenuated by the over-
expression of PRDX6. Collectively, these findings provide a
foundation for rational use of antioxidant-based therapeu-
tics for treating or preventing/delaying RGC death from
ROS driven oxidative stress under hypoxic conditions.
Methods
Culture of the retinal ganglion cell
R G C - 5( ak i n dg i f tf r o mN e e r a jA g a r w a l ,U n i v e r s i t yo f
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(DMEM) containing 10% fetal bovine serum (FBS), 100
U/ml penicillin and 100 μl/ml streptomycin at 37°C
with 5% CO2. The cells reaching confluency were trypsi-
nized and subcultured using 1:20 split. RGCs of 5 to 7
passages were used to carry out the experiments.
Generation of Hypoxic conditions
Cells were either exposed to 1% oxygen using hypoxic
chamber or they were treated with cobalt chloride, a
hypoxia mimic [60,61] at various concentrations and for
various time intervals.
Cell survival assays: MTS and TUNEL assays
Cells (1 × 10
4) were grown in 48 well plates and treated
with 50, 100, 150, 200 or 400 μMo fC o C l 2 for 24, 48 or
72 h. After treatment period, a colorimetric MTS assay
(Promega) was performed as described earlier [37]. This
assay of cellular proliferation uses 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2 to 4-sulfophenyl)-
2H-tetrazo-lium salt (MTS; Promega, Madison, MI).
Upon being added to medium containing viable cells,
MTS is reduced to a water-soluble formazan salt. The
A490 nm value was measured after cobalt chloride treat-
ment at specified duration with an ELISA reader. The
values are represented as a percent change to matched
controls within cell types.
A TUNEL assay was employed to assess and validate
apoptotic cell death. TUNEL staining was performed
using an in situ cell death detection kit, Fluorescein
(Roche Diagnostics GmbH, Germany), following the
company’s protocol. Briefly, cells were grown in 4 cham-
b e r e ds l i d e ,w a s h e dw i t hP B Sa n df i x e di nf r e s h l yp r e -
pared 4% paraformaldehyde in PBS (pH 7.4), followed
by incubation in permeabilization solution (0.1% Triton
X-100, 0.1% sodium citrate) for 2 min on ice. Cells were
rinsed twice with PBS, and incubated in a TUNEL reac-
tion mixture for 60 min at 37°C in the dark. Cells were
rinsed three times with PBS. After mounting, samples
were microphotographed using a micro-scope (Nikon,
ECLIPSE TE 300), and analyzed. To determine the total
dead cells, other than only the apoptotic cells, RGCs
were stained with trypan blue solution (0.4%), where
non viable cells are stained with trypan blue which is
normally excluded by the live cells.
Construction of Prdx6 Promoter-Chloramphenicol Acetyl-
transferase (CAT) Reporter Vector
The 5’-flanking region from -1139 to +109 bp was iso-
lated from mouse genomic DNA and sequenced [10]. A
construct of -1139 bp was prepared by ligating it to
basic pCAT vector (Promega) using the SacI and XhoI
sites. Similarly, construct of deletion mutants of differ-
ent sizes (- 839 to + 109 bp, construct B; -430 to + 109
bp, construct C) of the Prdx6 promoter with appropriate
sense primers bearing SacI and reverse primer with
XhoI were made [10]. The plasmid was amplified and
used for the CAT assay. Primers were as follows: Con-
struct Afor,5 ’-CTGAGAGCTCCTGCCATGTTC-3’;
Construct Bfor,5 ’ CTTCCTCTGGAGCTCAGAATT-
TAC-3’;C o n s t r u c tC for,5 ’-CACAG-AGCTCGTTCTTG
CCACATC-3’;C o n s t r u c t sA ,B ,a n dC rev,5 ’-CAGGA
ACTCGAGGAAGCGGAT-3’. We used construct B in
the present study.
Assay for intracellular redox state
Intracellular redox state levels were measured using the
fluorescent dye, H2-DCFH-DA as described earlier
[37,43]. Briefly, cells were washed once with HBSS and
incubated in the same buffer containing 5-10 μgo f
DCFH-DA for 30 min at 37°C. Intracellular fluorescence
was detected with Ex485/Em530 using Spectra Max
Gemini EM (Molecular Devices, CA).
Western analysis
Nuclear, cytoplasmic extracts and total Cell lysates were
prepared as described previously [10]. Equal amounts of
protein samples were loaded onto a 10% SDS gel,
blotted onto PVDF membrane, and immune-stained
with primary antibodies; PRDX6 monoclonal antibody
(1:1000) (Lab Frontier, S. Korea), NF- B (p65) (Santa
Cruz Biotech) and b-actin antibody (Sigma) (1:2000).
The membranes were further incubated with horserad-
ish peroxidase-conjugated secondary antibodies (1:1500
dilution) following washing. Specific protein bands were
visualized by incubating the membrane with luminol
reagent (Santa Cruz Biotechnology) and exposing to
film (X-OMAT; Eastman Kodak).
Real-time PCR
To monitor the levels of Prdx6, NF- B (p65), and b-actin
mRNA in RGCs, total RNA was isolated using the single-
step guanidine thiocyanate/phenol/chloroform extraction
method (Trizol Reagent; Invitrogen) and converted to
cDNA using Superscript II RNAase H-Reverse Transcrip-
tase. Quantitative real-time PCR was performed with
SYBR Green Master Mix (Roche Diagnostic Corporation,
Indianapolis, IN) in a Roche® LC480 Sequence detector
system (Roche Diagnostic Corporation). We used primers
specific for Prdx6 (forward 5’-TTGATGATAAGGG-
CAGGGAC-3’ and reverse, 5’-CTACCATCACGCTCTC
TCCC-3’), NF-B( f o r w a r d5 ’-TTTCCCCTCATCTTT
CCCTC-3’ and reverse 5’-TGTGCTTCTCTCCCCAGG-
3’)a n db-actin (forward 5’-CGTGGGCCGCCCTAGG-
CACCA-3’ and reverse 5’-TTGGCCTTAGGGTTCAGG
GGGG-3’). The primers were synthesized at University of
Nebraska Medical Center, DNA Facility, Omaha, NE,
USA. The comparative Ct method was used to calculate
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The Cts of target genes were normalized to the levels of b-
actin as an endogenous control in each group.
Expression and purification of GFP-PRDX6 fusion protein
Af u l ll e n g t hc D N Ao fP r d x 6w a si s o l a t e df r o mh u m a n
lens epithelial cell cDNA library using sense (5’-
ATGCCCGGAGGTCTGCTTCTCGGGG-3’)a n da n t i -
sense (3’-AATTGGCAG CTGACATCCTCTGGCTC-3’)
primers, and the resultant amplified product was cloned
in pcDNA3.1/NT-GFP-TOPO vector procured from
Invitrogen [40]. This construct was used for over-
expressing PRDX6 in RGCs. Cells transfected with
empty GFP vector served as control.
Statistical method
Data are presented as Mean ± S.D. of the indicated
number of experiments. Data were analyzed by Student’s
t-test when appropriate. A p value of < 0.05 was defined
as indicating a statistically significant difference.
Results
Hypoxia induced RGC death with apoptosis, and these
cells harbored elevated ROS, reduced PRDX6, and
increased NF-B expression
Recently reports have documented that hypoxia-induced
elevation in intracellular ROS is a cause of pathophysiol-
ogy in cells and tissues [62]. However, hypoxia exerts
both proapoptotic and antiapoptotic biphasic effects that
seem to be associated with cell types and conditions sur-
rounding the cells. In the present study, we initially used
the hypoxia-mimetic agentc o b a l tc h l o r i d e( C o C l 2)t o
expose RGCs to hypoxic stress. We examined whether
RGCs exposed to such stress showed reduced survival
and died with apoptosis and displayed higher ROS levels.
Results from cells exposed to cobalt chloride were com-
pared with those from RGCs exposed to 1% O2.
Cells exposed to cobalt chloride showed decrease in
cell survival, with levels depending on concentration and
exposure time (Figure 1A; black bars). Exposure of
RGCs to 1% oxygen for 24 h or 48 h resulted in cell
death in a time-dependent manner (Figure 1B; black
bars). With both types of exposure, the cellular effects
produced by hypoxia were associated with concentration
as well as the duration of exposure. These cells were
photomicrographed and recorded (Figures 2A-C. arrow;
dead cells). The mode of RGC death was apoptosis fol-
lowing treatment with CoCl2 (Figure 2B) or 1% O2
exposure (Figure 2C) after 48 h when compared to
unexposed cells (Figure 2A), as shown by TUNEL assay
(Figure 2 insets).
Next, to determine whether RGCs exposed to either
CoCl2 or 1% O2 bore higher levels of ROS, we moni-
tored the levels with the fluorescent dye, H2-DCFH-DA.
Consistent with earlier reports, an increase in ROS
levels was observed in cells exposed to hypoxic stress,
and the levels of ROS were increased with increased
time of exposure (Figures 3A and 3B; black bars).
Because reduced expression of intracellular PRDX6 is
causally related to increase expression of ROS, and NF-
B is a regulator of PRDX6 in cells in the redox state
[9,10,43,45], we next examined whether levels of these
two molecules were altered in cells under conditions of
hypoxia. We conducted Western analysis with PRDX6-
specific antibody, and the same blotted membrane was
reprobed with NF-B antibody following restriping. As
expected, reduced expression of PRDX6 (Figure 4,
PRDX6, 48 h or 72 h, lanes 2-4; Figure 5, PRDX6, 48 h,
lane 2) and elevated expression of NF-B( F i g u r e4 ,N F -
B, 24, 48 or 72 h, lanes 2-4; Figure 5, NF-B, 24 or 48 h,
lanes 2 and 4) were observed in cells exposed to hypoxia
(48 h onwards) (Because the higher dose of cobalt chlor-
ide [400 μM] caused ~ 70% of the RGC death, that dose
was excluded). Levels of PRDX6 were found to be
increased when analyzed after 24 h of hypoxia exposure
generated by cobalt chloride (50, 100 or 200 μM) or 1%
oxygen (Figure 4, PRDX6, 24 h, lanes 2-4; Figure 5,
PRDX6, 24 h, lane 2). The data illustrate the role of
PRDX6 in RGC survival under hypoxia exposure.
Modulation of PRDX6 and NF-B in RGCs during hypoxia
was due to repression of their transcription
Although it was confirmed at the protein level that the
expression of PRDX6 and NF-B was modulated under
hypoxia, it was not clear whether the changes in expres-
sion were due to modulation in the translation or in the
transcription of these molecules. To clarify the regula-
tion of PRDX6 and/or NF-B by hypoxic stress at the
transcriptional level, the cells were exposed to cobalt
chloride (50, 100 or 200 μM) or to 1% O2 as described
above for 24 h, and the mRNA from these cells was
used to conduct real time PCR. Results demonstrated
that RGCs exposed to hypoxia had an abundance of
Prdx6 mRNA, but levels of NF-Bm R N Aw e r en o t
found to be dramatically high when compared to the
controls (Figure 6A; black bars). To validate further acti-
vation of PRDX6 during hypoxia, we performed transac-
tivation assays as described in Methods. RGCs were
transfected with Prdx6 promoter linked to CAT con-
struct B [10], and were exposed to hypoxia either by
treating the cells with cobalt chloride (50, 100 or 200
μM) or by exposing to 1% oxygen. After exposure to
various concentrations of cobalt chloride (Figure 6B;
black bars) or 1% oxygen (Figure 6C; black bar) a pro-
nounced activation in Prdx6 promoter activity could be
observed, suggesting that Prdx6 is transcriptionally regu-
lated in RGCs under hypoxia. This finding indicates that
Prdx6 is upregulated to counteract hypoxia-induced
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apoptotic role in RGC death.
Hypoxia induced activation of NF-B and its translocation
into nucleus was associated with IkB phosphorylation/
degradation
To examine the dynamics of NF-B and IkB interactions
under hypoxia, cells were exposed to 200 μM of cobalt
chloride and subcellular fractions were assayed by Wes-
tern blot NF-B (p65) nuclear translocation (Figure 7A)
and IkB phosphorylation/degradation (Figure 7C).
Under normal circumstances, cytoplasmic NF-Bi s
inactive through interactions with an inhibitor protein
IkB. The phosphorylation of IkB unmasks the nuclear
t r a n s l o c a t i o ns i g n a lo nt h eN F - B. In the present study,
cells treated with cobalt chloride showed decreased
Figure 1 MTS assay showing effect of hypoxia on the viability of RGCs. Cells (1 × 10
4) were cultured in 48-well plate containing DMEM
supplemented with 10% FBS. 24 h later, cells were washed and treated with variable concentrations of cobalt chloride (A; black bars 50, 100,
200 or 400 μM) or exposed to 1% O2 (B; black bar) for a period of 24, 48 or 72 h. Results are means ± SE of three individual experiments.
*p < 0.05.
Figure 2 Photomicrograph of RGCs without (A) or with CoCl2 (B) or exposed to 1% O2 (C). Arrow heads denote dead cells. TUNEL staining
was performed as described in ‘Methods’ section to determine apoptotic RGC death following treatment. Insets: Photomicrograph of TUNEL-
positive cells (green fluorescent) treated without (A) or with (B) or exposed to 1% O2 (C).
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increase in phospho-IkB levels (Figure 7D; pIkB, lane 2).
The results revealed that kinetics of the increase in p65
in nucleus mirrors the kinetics for phosphorylation and
degradation of IkB in cytoplasmic fraction. Further acti-
vation of NF-B was confirmed by transactivation assay;
RGCs transfected with pLTR-CAT construct, which
consists of two NF-B sites [43], were subjected to
hypoxic stress (1% O2) for 24 h. CAT activity assessed
with CAT-ELISA as described in Methods revealed acti-
vation of NF-B (Figure 9C, dark gray bar). Collectively,
the findings demonstrate activation of NF-Bb y
hypoxia.
PRDX6 over-expression attenuated hypoxia-induced RGC
death, by reducing ROS production and optimizing NF-B
activation
PRDX6 exerts its protective function by regulating ROS
expression and blocking cell death signaling. To deter-
mine the efficacy of PRDX6 in abolishing hypoxia-
evoked ROS-driven damage to and death of RGCs, we
transfected RGCs with pGFP-PRDX6 (2, 4 and 6 μg) as
described in Experimental Procedures, and transfection
efficiency was equalized with OD obtained from GFP
fluorescence at Ex485/Em530. We also confirmed over-
expression of pGFP-PRDX6 using Western analysis (Fig-
ure 8A) As expected, RGCs over-expressing PRDX6
showed reduced levels of ROS when they were exposed
to either cobalt chloride (Figure 8B; 50, 100 or 200 μM;
black bars) or 1% oxygen (Figure 8C; black bars). Cell
death was reduced by ~20% to 30% as observed in these
cells treated with various concentrations of the agents
compared to controls transfected with empty GFP vec-
tor (Figure 9A; black bars). Similar results were obtained
when PRDX6 over-expressed cells were exposed to 1%
oxygen (Figure 9B; black bars). To test whether PRDX6
administration attenuated NF-B activation in RGCs fol-
lowing hypoxia treatment, we did transactivation assay
in RGCs using pLTR-CAT construct (Figure 9C).
Results showed an increase in the promoter activity fol-
lowing hypoxia (1% oxygen) and the increase could be
inhibited by a supply of PRDX6 (Figure 9C; black bar).
Western analysis further confirmed that extrinsic supply
of PRDX6 reduced expression of NF-Bi nR G C s
exposed to hypoxia (Figure 9D; NF-B; lane 3). Taken
together, the results demonstrated that PRDX6 protects
against hypoxia-evoked oxidative stress mediated cell
death by restoring survival signaling, at least in RGCs,
Figure 3 Histogram showing intracellular ROS expression in RGCs following CoCl2 treatment or 1% O2 exposure. Cells were treated with
different concentrations of cobalt chloride (50, 100, 200 or 400 μM) (A) or exposed to1% oxygen (B) for a period of 24, 48 or 72 h. ROS were
measured with H2-DCFH-DA dye. Results are means ± SE of 3 experiments. *p < 0.05
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Page 6 of 14Figure 4 Western analysis showing modulated expression of PRDX6 and NF-B protein in RGCs treated with CoCl2. Cells (4 × 10
5) were
cultured in 100 mm culture plates, and after 24 h these cells were treated with different concentrations of CoCl2 (50, 100, 200 μM) for a period
of 24, 48 or 72 h. After treatment, cell extracts were prepared for Western analysis. A significant reduction of PRDX6 protein expression was
observed following treatment with 100 or 200 μM of CoCl2 at 72 h (upper panel, PRDX6; 72 h; lanes 2, 3 and 4, 48 h; lanes 3 and 4). In contrast,
an increase in NF-B protein level was observed (middle panel) while no change was detected in the expression of b-actin level (lower panel),
suggesting hypoxia specifically reduced the expression of PRDX6. Histogram shows relative density (Pixels) of protein bands. *p < 0.05.
Figure 5 Effect of Hypoxic stress on regulation of PRDX6 and NF-B proteins in RGCs exposed to 1% O2. Cells (4 × 10
5) were cultured in
100 mm culture plates, and after 24 h these cells were exposed to 1% O2 for a period of 24 and 48 h. After treatment, cell extracts were
prepared for Western analysis. A significant increase in PRDX6 protein expression was observed after 24 h and reduced after 48 h of 1% O2
exposure (lane 2). In contrast, an increase in NF-B protein level was observed (middle panel) while no change was detected in the expression
of b-actin level (lower panel), suggesting hypoxia specifically reduced the expression of PRDX6. Histogram shows relative density (Pixels) of
protein bands. *p < 0.05.
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activation and expression.
Discussion
Changes in oxidant and antioxidant balance may alter
cellular homeostasis; cells may go through survival or
death pathways, depending upon expression of ROS and
antioxidant defense capacity. Eye tissues are constantly
exposed to external and internal environmental stresses
such as sunlight, chemical irritations, and hypoxia.
These stressors may lead to blinding disorders of the
eye by inducing abnormalities in the homeostatic system
of cells. Interruption of normal blood flow to an organ
causes ischemia-hypoxia, which can result in tissue
injury in many organs, including the heart, liver, lungs,
and retina, all physiologically active tissues. Stresses or
deficiency of O2 (hypoxia) in retinal tissues may cause
severe damage, subsequently leading to blinding disease.
The manner in which chronic hypoxia causes cell or
tissue damage or cell death has been described in sev-
eral recent reports documenting that the hypoxia evokes
overproduction of ROS, which are a major culprit in cell
damage [11]. Moreover, as a physiologically active tissue,
the retina requires large quantities of oxygen [11], and
fluctuations in oxygen level may alter the entire retinal
physiology and lead to failure of homeostasis [11]. Sys-
temic hypoxemia caused by lung or heart disease or a
vascular disease in the retina can also cause retinal
h y p o x i aa n db eam a j o rc a u s eo fR G Cl o s s .R e c e n te v i -
dence reveals that chronic hypoxia attenuates the cellu-
lar prooxidant-antioxidant balance by accumulation of
ROS [63], and this condition has been implicated in
progressive neurodegenerative diseases. We believe that
chronic hypoxia may be associated with reduced expres-
sion and activity of survival molecules and antioxidants
such as PRDX6 [9,10,37,42,43,64]. In the present study,
we found that RGCs exposed to hypoxia displayed ele-
vated expression of ROS, which was associated with
reduced expression of PRDX6 (Figures 3, 4 and 5), and
these cells underwent apoptosis (Figure 2). These results
are consistent with earlier findings that human pulmon-
ary and coronary artery smooth muscle cells bear higher
levels of ROS, and the elevated levels of ROS are a
major damaging factor [65]. Moreover, ROS is source of
oxidative stress, has gained more and more attention
recently because of its role as a cellular signaling for a
various molecules released from activated glia or micro-
glia such as glutamate [9], cytokines such as TNF-a and
growth factors [9,10]. The production of ROS by these
molecules has been associated with activation or
Figure 6 Quantitative PCR showing differential expression of Prdx6 and NF-B mRNA in RGCs with or without treatment with CoCl2 or
exposed to 1% O2. Total RNA was isolated and transcribed into cDNA. PCR was performed using specific primers as described in ‘Methods’
section. mRNA expression of each Prdx6 and NF-B was adjusted to the mRNA copies of b-actin. Results indicate that mRNA expression level of
Prdx6 was significantly increased after 24 h of exposure to different concentrations of CoCl2 (A; 50, 100 or 200 μM) with an increase of NF-B
mRNA. (B) CAT assay showing promoter activity of Prdx6 following hypoxia. Cells were transiently transfected with Prdx6-CAT (B & C). After 24 h
of transfection, cells were either treated with cobalt chloride (50, 100 or 200 μM) (B) or exposed to 1% O2 (C; black bar). Transactivation assay
was performed after 72 h of transfection. Results indicate that Prdx6 transcription (B and C) was up-regulated following cobalt chloride or 1% O2
exposure, respectively. *p < 0.05.
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Page 8 of 14deactivation of several transcription factors [8-10,12,43].
We think that elevated levels of inflammatory cytokines
in the microenvironment of RGCs are responsible for
further elevation of ROS in RGCs that leads RGCs
death. Recently, we reported that PRDX6 delivery to
RGCs can protect against glutamate or TNF-a mediated
cytotoxicity, and that the PRDX6 acts by removing ROS
and stabilizing NF-B activation. Notably, both PRDX6
and NF-B are producers of ROS. While there is much
discussion in the research community about increase or
decrease of ROS expression during hypoxia, the present
study provides evidence that longer periods of hypoxia
generate ROS, and ROS-induced abnormal signaling is a
major cause of RGC damage or death (Figures 1, 2 and
3). Our data further support our hypothesis that hypoxia
induces ROS; RGCs that over-expressed PRDX6 showed
resistance against hypoxic stress, reduced ROS expres-
sion, and improved survival. Along with others,
we have shown that PRDX6 blocks ROS-mediated
pathophysiology that occurs during cataractogenesis,
neurological disorders, and diabetic-associated disorders
[9,42,43], and plays a pivotal role in maintaining lung
cell homeostasis [44,48,66-68]. Moreover, our current
study revealed that (i) hypoxia evokes intracellular ROS
accumulation, which increases with an increase in time,
(ii) ROS elevation is causally related to RGC death, and
(iii) PRDX6 can attenuate hypoxia-generated oxidative
stress-induced RGC death.
Recently, several reports have shown that hypoxic
stress induces ROS production, which, if not quenched,
leads to cellular pathophysiology [63,65,69,70]. Using a
cell culture system, we found that RGCs exposed to
either 1% oxygen (physiological hypoxia) or treated with
cobalt chloride, a hypoxia mimetic (chemical hypoxia),
display elevated expression of ROS (Figure 2) We
observed ~30%-60% RGC death in cells with physiologi-
cal hypoxia (1% oxygen) and ~30%-70% death with
cobalt chloride treatment (Figure 1). These data are con-
sistent with previous studies which observed ~25% RGC
death after 12 h of exposure to 5% oxygen [71], ~30%
cell death after 24 h of 200 μMC o C l 2 treatment
and found that RGC death following hypoxia was predo-
minantly apoptotic, although both apoptotic and necro-
tic cell death have been observed [71,72]. Furthermore,
in glaucomatous eyes, selective loss of RGCs occurs
[73], and these cells are particularly sensitive to systemic
h y p o x i cs t r e s s[ 7 4 ]a sar e s u l to fl o n g - t e r mo x i d a t i v e
damage induced by ROS [75].
Interestingly, our present study found increased
expression of PRDX6 for the first 24 h of hypoxia expo-
sure (Figures 4 and 5), but when hypoxia exposure was
prolonged, the expression of PRDX6 was reduced, and
the reduction was related to cell death. Thus our results
demonstrate a novel mechanism of hypoxia regulation
of PRDX6, in which concentration and time of exposure
o fR G C st oh y p o x i ap l a yp i v o t a lr o l e si nd e t e r m i n i n g
the fate of the RGCs, which is dependent upon PRDX6
expression. Our study further demonstrated that ele-
vated levels of ROS in RGCs caused by hypoxia are a
major cause of cell death, and that the increase in ROS
can be eliminated by over-expression of PRDX6 (Figures
8 and 9). As other Prdxs did not counteract the changes
in RGCs, we consider the role of PRDX6 to be pivotal,
at least in those cells. Interestingly, we also found that
acute hypoxia is beneficial to RGCs, as the acute condi-
tion may attenuate the extent of cellular ROS and pro-
vide an adaptive control mechanism. If that is the case,
RGC death during eye disorders including glaucoma is
probably caused by the cumulative effect of hypoxia
over time, which produces ROS-driven oxidative
damage. Moreover, elevated ROS expression has been
observed in rabbit retinal cells during ischemia induced
by high IOP [76]. We have reported that lens epithelial
Figure 7 Western analysis showing NF-B translocation in
nucleus from cytoplasm and phosphorylation of IkBa in RGCs
facing hypoxic stress. Cell (4 × 10
5) were cultured in 10 mm
culture plates and were treated with 200 μM of CoCl2 for 2 h. After
treatment, cytoplasmic and nuclear extracts were prepared for
western analysis. Cells treated with CoCl2 showed increased
expression of NF-B in nucleus (A, NF-B, lane 2) with concomitant
decrease in cytoplasmic expression (B, NF-B, lane 2). These cells
showed reduced expression of IkB (C; lane 2) and enhanced
expression of its phosphorylated form pIkB in cytoplasm (D; lane 2).
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Page 9 of 14cells (LECs) deficient in PRDX6 bear higher levels of
ROS, are vulnerable to oxidative stress, and undergo
spontaneous apoptosis [37]. Collectively, our results sug-
gest that the reduced expression of PRDX6 in RGCs
exposed to hypoxia may be one cause of RGC death.
Moreover, ROS-driven oxidative stress has been related
to a number of diseases and disorders. In fact, it is pos-
sible that most pathology involves oxidative stress, at
least to some extent, and this may occur due to sup-
pression of antioxidants such as PRDX6. Our present
work has demonstrated that hypoxia suppresses PRDX6
expression, leading in turn to RGC death.
The identification of genes or their products involved
in etiology of oxidant-mediated pathology has already led
to important insights into the cellular response to stress
and mechanisms of oxidant damage. In previous reports,
we described the regulation of PRDX6 gene expression
by NF-B [9,10], and the dependence of PRDX6 expres-
sion level upon cellular redox state. However, when
expression levels of ROS exceed the control of cellular
antioxidants, cells die by apoptosis or necrosis. We
believe that optimizing the level of ROS by the delivery
of PRDX6 should prevent or delay ROS-induced deleter-
ious signaling. Furthermore, the generation of ROS has
been associated with the activation and deactivation of
the transcriptional protein NF-B [77,78]. Modulation in
the activity of NF-B in neuronal cells is strongly asso-
ciated with cellular fate, and NF-B can have either an
antiapoptotic or proapoptotic function [79,80], depend-
ing on cell type or cellular microenvironment
[29,30,81,82]. Importantly, in RGCs, activation of NF-B
has been found to induce apoptotic signaling, and
Figure 9 PRDX6 regulation of NF-kB expression and cellular survival during hypoxia (A). MTS assay showing protective effect of over-
expression of PRDX6 on RGCs survival. Cells were transiently transfected with either GFP vector or GFP-PRDX6. After 24 h cells were either
treated with CoCl2 (50, 100 or 200 μM) or exposed to 1% O2. Results indicate that GFP-PRDX6 over-expression significantly reduced death of
RGCs exposed to CoCl2 (A; 50, 100 or 200 μM) or 1% O2 (B). To monitor the activation of NF-B, cells were transfected with GFP vector or GFP-
PRDX6. These cells were co-transfected with HIV-1LTR-CAT construct (C) having NF-B sites [37] and were exposed to 1% O2. Results showed the
repression of NF-B-dependent transcriptional activation of HIV-1LTR in cells over-expressing PRDX6 (C; black bar). In parallel experiments, cell
extracts was prepared and Western analysis performed to confirm whether GFP-PRDX6 over-expression reduced the expression of NF-B (D).
Upper panel showing decreased expression of NF-B in nuclear extract of RGCs over-expressing PRDX6.
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Page 10 of 14suppression of its activation significantly enhances the
viability of RGCs [30]. Our results also vividly demon-
strate that addition of PRDX6 in RGCs attenuates NF-B
activation induced by hypoxia, suggesting that PRDX6
can block the NF-B-induced death pathway in RGCs.
We believe the survival of RGCs is associated with of
NF-B activation in acute hypoxia, since upregulation of
PRDX6 would be able to remove ROS, while hyperactiva-
tion or inadequate activation of NF-Bi nR G C sm a yb e
disastrous. Thus, modulation of NF-B activation should
be an important strategy for reducing cellular injury.
Overall, it appears that RGC death induced by hypoxia
should also be associated with hyper-activation of NF-B
due to higher levels of ROS during glaucoma or other
neurological diseases. The activation of NF-B is seen in
various cell types in response to hypoxia. Hypoxia
induced activation of NF-B occurs through IkB activa-
tion and its phosphorylation [83,84]. In this study, we
found that hypoxia exposure activates NF-Bw i t hi t s
subsequent translocation into nucleus. We also found
increased phosphorylation of IkB in RGCs following
hypoxia. These findings suggest that NF-B activation in
RGCs under hypoxic conditions involves the activation of
the canonical pathway through degradation/phosphoryla-
tion of the IkBa. Our data demonstrate that cells over-
expressed with PRDX6 protect the RGCs from hypoxia-
induced oxidative stress by removing ROS and thereby
normalizing NF-B activation.
Figure 8 Effect of over-expression of GFP-PRDX6 on ROS levels in RGCs following hypoxic stress. Cellular extract was prepared and
resolved on SDS-PAGE, and Western analysis was performed using antibody specific to PRDX6, to assess both exogenous and endogenous
expression of PRDX6. ~55 kDa protein band was detected as recombinant GFP-PRDX6 protein (A, right lane). Histogram showing ROS levels in
RGCs after exposure to hypoxia (B&C). Cells over-expressed with GFP-PRDX6 prevented excessive generation of ROS against CoCl2 (50, 100 or 200
μM). Cells were transiently transfected with either GFP vector or GFP-PRDX6. After 24 h cells treated with CoCl2 (50, 100 or 200 μM).
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We have found that hypoxia induces ROS-driven RGC
death caused by down regulation of PRDX6 in cells
under prolonged hypoxia, and ROS expression is cau-
sally associated with PRDX6 expression level. Results
further revealed that ROS are differentially regulated
during hypoxia; however, increased expression of ROS,
due to deficiency of PRDX6, indeed reflects pathophy-
siology of RGCs. Because delivery of PRDX6 may
attenuate RGC death by optimizing intracellular ROS
and NF-B activation, PRDX6 should be considered as
therapeutic agent for hypoxia-induced disorders. Further
detailed research will be needed to elucidate the
mechanisms involved in the PRDX6-mediated protection
of RGCs.
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